Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia 1

Interventions

Cytarabine 18Daunorubicin 13Etoposide 12Filgrastim 8Mitoxantrone 7Peripheral Blood Stem Cell Transplantation 6Idarubicin 6Radiotherapy 4Observation 4Gemtuzumab 4Cyclophosphamide 4valspodar 3aldesleukin 3Tretinoin 3Busulfan 3sargramostim 2Watchful Waiting 2Thioguanine 2Granulocyte Colony-Stimulating Factor 2Amsacrine 2zosuquidar trihydrochloride 1tipifarnib 1midostaurin 1lintuzumab 1laromustine 1fludarabine phosphate 1flt3 ligand protein 1etoposide phosphate 1dexamethasone acetate 1Mesna 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Leukemia, Megakaryoblastic, Acute × lintuzumab × Clear all
NCT00006045 2013-11-06

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia

National Cancer Institute (NCI)

Phase 3 Unknown
Other hematologic neoplasm

Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡